ADVANTAGENE, INC

Address

440 Lexington St
AUBURNDALE, MA, 02466-1923

Information

DUNS: 192959851
# of Employees: N/A

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Immuno-Oncology for Pancreatic Cancer: A Combination Clinical Trial with Chemotherapy and Radiation

    Amount: $299,985.00

    DESCRIPTION provided by applicant Pancreatic adenocarcinoma has a dismal year survival of andlt The only potential curative treatment is resection but this is achieved in andlt of patien ...

    SBIRPhase I2016Department of Health and Human Services
  2. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    Amount: $224,999.00

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhos ...

    SBIRPhase I2014Department of Health and Human Services
  3. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    Amount: $7,226,590.00

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

    SBIRPhase II2009Department of Health and Human Services
  4. Improved system for producing adenoviral vectors

    Amount: $213,871.00

    First generation non-replicative adenoviral vectors show promise as anti-cancer agents and as prophylactic vaccines. Current methods for manufacturing these vectors use either the 293 cell line or t ...

    SBIRPhase I2007Department of Health and Human Services
  5. Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer

    Amount: $101,130.00

    DESCRIPTION (provided by applicant): The main objective of this project is to develop a new therapeutic to improve the outcome for patients with intermediate-risk prostate cancer. The indication is a ...

    SBIRPhase I2007Department of Health and Human Services
  6. Clinical study of AdV-tk radiogenetherapy for malignant*

    Amount: $788,188.00

    DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

    SBIRPhase II2007Department of Health and Human Services
  7. Clinical study of GMCI in Pancreatic Cancer

    Amount: $747,384.00

    DESCRIPTION (provided by applicant): Pancreatic adenocarcinoma is the fourth leading cause of cancer deaths in the US; with less than one-year median survival, it accounts for approximately 30,000 dia ...

    SBIRPhase I2006Department of Health and Human Services
  8. Clinical study of AdV-tk radiogene therapy for glioma

    Amount: $758,386.00

    DESCRIPTION (provided by applicant): Malignant gliomas have a very poor prognosis with median survival measured in months rather than years. It is a disease with great need of novel therapeutic appr ...

    SBIRPhase I2004Department of Health and Human Services
  9. Combination of GM-CSF with TKR gene therapy

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): Combined gene therapy (Herpes Simplex Virus Thymidine Kinase + Anti-herpetic Prodrug) and radiation therapy (TKR therapy) is a novel approach in the armamentarium ...

    SBIRPhase I2003Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government